U.S. markets closed
  • S&P Futures

    4,219.00
    +9.00 (+0.21%)
     
  • Dow Futures

    33,337.00
    +77.00 (+0.23%)
     
  • Nasdaq Futures

    13,440.00
    +48.00 (+0.36%)
     
  • Russell 2000 Futures

    1,973.90
    +4.40 (+0.22%)
     
  • Crude Oil

    91.67
    -0.26 (-0.28%)
     
  • Gold

    1,801.80
    -11.90 (-0.66%)
     
  • Silver

    20.49
    -0.25 (-1.21%)
     
  • EUR/USD

    1.0290
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2191
    -0.0027 (-0.22%)
     
  • USD/JPY

    133.0930
    +0.2200 (+0.17%)
     
  • BTC-USD

    24,333.24
    +1,448.83 (+6.33%)
     
  • CMC Crypto 200

    573.52
    +42.30 (+7.96%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RedHill Biopharma RDHL announced data from a preclinical in vivo study, evaluating its COVID-19 drug Opaganib in kidney inflammation and fibrosis. Data from the study demonstrated that Opaganib achieved efficacy in significantly reducing renal fibrosis in patients with chronic kidney disease (“CKD”) in a well characterized unilateral ureteral obstruction model.

Shares of RedHill have rallied 18.2% so far this year against the industry’s 9.6% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In CKD patients, renal fibrosis is a progressive process that may result in end-stage renal failure. COVID-19 and long COVID patients also have a high risk of kidney damage.

More than 20% of hospitalized COVID patients experience acute renal failure. Acute kidney injury –- a potential consequence of COVID-19 –- results in the inability of the kidneys to be repaired properly. Opaganib inhibits the sphingosine kinase-2, a key enzyme that is part of the process that prevents the kidney from repairing itself and replicating the COVID-19 virus.

It is to be noted that Opaganib, an oral pill drug candidate with dual anti-inflammatory and antiviral activity, is currently being evaluated in a phase II/III study in hospitalized patients with COVID-19. This study has completed treatment and follow up phase, with top-line results expected shortly.

The company recently announced positive preliminary results from a new preclinical study on Opaganib. The drug demonstrated strong inhibition of delta variant of the COVID virus in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date.

Redhill Biopharma Ltd. Price

Redhill Biopharma Ltd. Price
Redhill Biopharma Ltd. Price

Redhill Biopharma Ltd. price | Redhill Biopharma Ltd. Quote

Zacks Rank & Stocks to Consider

RedHill currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech/drug sector include Ironwood Pharmaceuticals IRWD, Regeneron Pharmaceuticals REGN and Repligen Corporation RGEN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Ironwood’s earnings per share estimates for 2021 have increased from $1.00 to $1.18 in the past 60 days. The same for 2022 has risen from $1.18 to $1.72 over the same period. The stock has rallied 10.3% in the year so far.

Regeneron’s earnings per share estimates for 2021 have increased from $49.51 to $54.15 in the past 60 days. The same for 2022 has risen from $41.30 to $44.11 over the same period. The stock has rallied 38.4% in the year so far.

Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 60 days. The same for 2022 has risen from $2.56 to $3.02 over the same period. The stock has rallied 54.6% in the year so far.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report

Repligen Corporation (RGEN) : Free Stock Analysis Report

Redhill Biopharma Ltd. (RDHL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research